Tandem Diabetes Care (TNDM) Projected to Post Earnings on Thursday

Key Points

• Tandem Diabetes Care will report Q1 2026 results after the market close on Thursday, May 7, 2026 (earnings call 4:30 PM ET); analysts expect ($0.46) EPS and $242.085 million in revenue.
• In the prior quarter the company beat estimates—reporting ($0.01) EPS vs. ($0.05) expected and $290.38 million in revenue (up 15.1% year‑over‑year)—but remains unprofitable with a negative ROE (68.23%) and net margin (‑20.17%).
• Shares trade around $18.16 with a market cap of $1.24 billion and a 1‑year range of $9.98–$29.65; analysts give a Moderate Buy consensus and a target price of $30.05, though individual targets vary widely (up to $56).

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) is projected to announce its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect the company to announce earnings of ($0.46) per share and revenue of $242.0850 million for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 7, 2026 at 4:30 PM ET.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.05) by $0.04. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.The business had revenue of $290.38 million for the quarter, compared to the consensus estimate of $277.14 million. During the same quarter last year, the business posted $0.01 EPS. The firm's revenue was up 15.1% compared to the same quarter last year. On average, analysts expect Tandem Diabetes Care to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Tandem Diabetes Care Stock Down 2.5%

NASDAQ:TNDM opened at $18.16 on Thursday. Tandem Diabetes Care has a 1 year low of $9.98 and a 1 year high of $29.65. The stock has a 50-day moving average price of $21.78 and a two-hundred day moving average price of $20.17. The stock has a market cap of $1.24 billion, a price-to-earnings ratio of -5.92 and a beta of 1.74. The company has a current ratio of 2.55, a quick ratio of 2.02 and a debt-to-equity ratio of 2.00.

Institutional Investors Weigh In On Tandem Diabetes Care

Several institutional investors have recently bought and sold shares of TNDM. Corient Private Wealth LLC bought a new position in shares of Tandem Diabetes Care during the 4th quarter worth approximately $346,000. Mercer Global Advisors Inc. ADV bought a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $248,000. EP Wealth Advisors LLC acquired a new position in Tandem Diabetes Care during the fourth quarter worth $219,000. Wellington Management Group LLP acquired a new position in Tandem Diabetes Care during the fourth quarter worth $2,161,000. Finally, Man Group plc bought a new position in Tandem Diabetes Care in the fourth quarter valued at $281,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on TNDM shares. Piper Sandler upgraded Tandem Diabetes Care from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $33.00 in a report on Tuesday, March 17th. Rothschild & Co Redburn set a $45.00 target price on shares of Tandem Diabetes Care in a report on Friday, April 24th. Morgan Stanley lifted their price target on shares of Tandem Diabetes Care from $23.00 to $25.00 and gave the company an "equal weight" rating in a research note on Monday, March 2nd. Mizuho set a $22.00 price target on shares of Tandem Diabetes Care and gave the company a "neutral" rating in a report on Friday, February 20th. Finally, Barclays reissued an "overweight" rating and set a $56.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.05.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.